You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Guidelines & Advice

About Guidelines Email Guidelines Team

Displaying Guidelines

18 Items

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Document Status: Current
ID: GL-END-C50-35

Aug 2023

Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Document Status: Current
ID: GL END 5-13
Version: N/A

Jun 2023

Cannabis and cannabinoids: Cancer risk and use to manage cancer symptoms

Document Status: Current
ID: N/A
Version: 2

Jan 2023

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Document Status: Current
ID: GL 21-6

Apr 2023

Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone

Document Status: Current
Version: 1.0

Mar 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2022

Document Status: Current
ID: PET 2022-1

Jan 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Document Status: Current
ID: PET 2023-1

Nov 2023

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2022

Document Status: Current
ID: PET 2022-2

Jun 2023

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Document Status: Current
Version: 1

Apr 2023

Management of Early-Stage Hodgkin Lymphoma

Document Status: Current
ID: GL 6-20
Version: 2

May 2023

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Document Status: Current
ID: GL-END 3-25

Nov 2023

Optimizing Ambulatory Systemic Treatment Models of Care

Document Status: Current
Version: 1

Jul 2023